The EU’s joint clinical assessment (JCA) initiative has been set up to accelerate patient access to new therapies, but could end up restricting the use of new technologies
Working in the pharma industry, it’s important to be aware of the impact of policies on all stakeholders, from industry colleagues, to payers and providers, and to patients – including low-
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.